Published in J Exp Med on March 01, 1984
Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A (1985) 7.15
Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med (1990) 6.35
Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun (1986) 4.34
Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med (1984) 4.00
Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4. Proc Natl Acad Sci U S A (1986) 2.47
Role of nitric oxide in parasitic infections. Microbiol Rev (1995) 1.91
Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun (1985) 1.82
Influences of gamma interferon on synovial fibroblast-like cells. Ia induction and inhibition of collagen synthesis. J Clin Invest (1985) 1.71
Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats. Clin Exp Immunol (1990) 1.53
Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol (1997) 1.43
Fungicidal activation of murine macrophages by recombinant gamma interferon. Infect Immun (1987) 1.30
Intracellular multiplication of Paracoccidioides brasiliensis in macrophages: killing and restriction of multiplication by activated macrophages. Infect Immun (1989) 1.25
Role of gamma interferon in induction of natural killer activity by Legionella pneumophila in vitro and in an experimental murine infection model. Infect Immun (1988) 1.12
Obligatory role of gamma interferon in T cell-replacing factor-dependent, antigen-specific murine B cell responses. J Exp Med (1985) 1.10
Co-operative effect of MCF and MAF(IFN-gamma) in the protection of mice against Listeria monocytogenes. Immunology (1988) 1.07
Lack of binding of bacterial lipopolysaccharide to mouse lung macrophages and restoration of binding by gamma interferon. J Exp Med (1985) 1.02
Activation of pulmonary macrophages for fungicidal activity by gamma-interferon or lymphokines. Clin Exp Immunol (1987) 1.00
Synergism between gamma interferon and lipopolysaccharide for synthesis of factor B, but not C2, in human fibroblasts. J Exp Med (1988) 0.99
In vivo activation of peripheral blood polymorphonuclear neutrophils by gamma interferon results in enhanced fungal killing. Infect Immun (1989) 0.90
Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. Proc Natl Acad Sci U S A (1985) 0.81
The bovine papillomavirus genome and its uses as a eukaryotic vector. Biochem J (1987) 0.80
T-cell-independent macrophage activation in mice induced with rRNA from Listeria monocytogenes and dimethyldioctadecylammonium bromide. Infect Immun (1986) 0.80
Unique properties of auranofin as a potential anti-rheumatic drug. Agents Actions (1986) 0.77
Induction of Ia antigens on synovial cells by gamma interferon. Korean J Intern Med (1987) 0.75
Augmented production of granulocyte-macrophage colony-stimulating factor and alpha/beta interferon in mice inoculated with heat-killed Corynebacterium liquefaciens. Infect Immun (1991) 0.75
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
Detection of endotoxin in human blood and demonstration of an inhibitor. J Lab Clin Med (1970) 6.04
Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med (1982) 5.33
Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci U S A (1983) 5.25
Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol (1983) 4.38
Cooperation of immune lymphoid cells with macrophages in tumour immunity. Nature (1970) 4.01
Macrophage tumor killing: influence of the local environment. Science (1977) 2.94
Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J Immunol (1983) 2.61
Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J Immunol (1981) 2.21
Regulation of murine macrophage Ia-antigen expression by products of activated spleen cells. J Exp Med (1980) 2.19
Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance. J Immunol (1976) 2.11
Macrophage activation by lymphocyte mediators. Fed Proc (1975) 1.99
Macrophages in resistance to rickettsial infections: characterization of lymphokines that induce rickettsiacidal activity in macrophages. J Immunol (1981) 1.94
Stimulation of RNA synthesis in L-929 cells by rabbit tumor necrosis factor. Proc Soc Exp Biol Med (1979) 1.83
Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. Proc Natl Acad Sci U S A (1983) 1.73
Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies. J Biol Chem (1981) 1.61
Antiviral activities of hybrids of two major human leukocyte interferons. Nucleic Acids Res (1981) 1.56
Regulation of macrophage tumoricidal function: a role for prostaglandins of the E series. Science (1978) 1.51
Evidence for the identity of murine gamma interferon and macrophage activating factor. J Interferon Res (1982) 1.48
Modulation of macrophage tumoricidal capability by components of normal serum: a central role for lipid. Science (1977) 1.35
Use of the ELISA to screen for anti-thymocyte and anti-beta 2-microglobulin antibodies in leprosy and SLE. Immunology (1980) 1.22
Activation in vitro of mouse macrophages by syngeneic, allogeneic, or xenogeneic lymphocyte supernatants. J Natl Cancer Inst (1975) 1.20
Antiviral activity of bacteria-derived human alpha interferons against encephalomyocarditis virus infection of mice. Infect Immun (1982) 1.19
Mononuclear phagocytes: responders to and producers of interferon. Ann N Y Acad Sci (1980) 1.17
Interferon activates macrophages to produce plasminogen activator. J Interferon Res (1982) 1.11
Endotoxin requirement for macrophage activation by lymphokines in a rapid microcytotoxicity assay. J Immunol Methods (1980) 1.10
Characterization of interleukin 2-dependent cytotoxic T-cell clones: specificity, cell surface phenotype, and susceptibility to blocking by Lyt antisera. Cancer Res (1983) 1.07
Similarities among factors that render macrophages tumoricidal in lymphokine and interferon preparations. Cancer Res (1978) 1.05
Similarities of murine gamma interferon and the lymphokine that renders macrophages cytotoxic. J Interferon Res (1982) 1.05
In vitro tumor cell destruction by syngeneic mouse macrophoages: methods for assaying cytotoxicity. J Immunol Methods (1975) 1.00
Murine T-cell hybridomas that produce lymphokine with macrophage-activating factor activity as a constitutive product. Cell Immunol (1982) 0.99
Requirement for magnesium influx in activation of alveolar macrophages mediated by ionophore A23187. Nature (1977) 0.96
Metabolic inhibitors render "resistant" target cells sensitive to natural killer cell-mediated lysis. Int J Cancer (1981) 0.93
Recognition and destruction of target cells by tumoricidal macrophages. Isr J Med Sci (1978) 0.92
Synergistic activation of macrophages by lymphokine and lipopolysaccharide: evidence for lymphokine as the primer and interferon as the trigger. J Interferon Res (1982) 0.91
Standardization of a sensitive and rapid assay for lymphotoxin. Cell Immunol (1975) 0.88
Factors affecting macrophage cytotoxic activity with particular emphasis on corticosteroids and acute stress. J Reticuloendothel Soc (1979) 0.87
Multiple lymphokine production by a phorbol ester-stimulated mouse thymoma: relationship to cell cycle events. J Natl Cancer Inst (1983) 0.86
The mechanism of macrophage activation induced by Ca2+ ionophore. Cell Immunol (1983) 0.86
Intracellular mediation of lymphokine action: mimicry of migration inhibitory factor (MIF) action by phorbol myristate acetate (PMA) and the ionophore A23187. Ann N Y Acad Sci (1979) 0.82
Characterization of interleukin 2-dependent cytotoxic T-cell clones. IV. Production of alpha, beta and gamma interferons and interleukin 2 by Lyt-2+ T cells. Cell Immunol (1983) 0.82
Endotoxin and macrophage-migration inhibition. Cell Immunol (1980) 0.81
Coproduction of interleukin-2 and interferon-gamma in human mononuclear cells. J Biol Response Mod (1983) 0.80
Historical overfishing and the recent collapse of coastal ecosystems. Science (2001) 33.78
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (1985) 13.04
Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature (1985) 12.08
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science (1985) 7.99
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature (1986) 7.90
Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol (1985) 7.20
Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem (1985) 6.28
Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature (1985) 5.41
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature (1983) 5.27
The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem (1978) 4.55
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res (1987) 4.44
Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci U S A (1985) 4.42
Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol (1985) 4.41
Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med (1987) 4.35
Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med (1984) 4.00
Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (1984) 3.98
TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell (1990) 3.86
Diversity of planktonic foraminifera in deep-sea sediments. Science (1970) 3.72
The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A (1991) 3.40
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
Structure of human factor VIII. Nature (1984) 3.29
Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci U S A (1991) 3.19
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med (1987) 3.03
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum (1988) 2.77
Dendritic cells initiate a two-stage mechanism for T lymphocyte proliferation. J Exp Med (1983) 2.76
Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol (1988) 2.74
Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A (1992) 2.73
Primary structure of human insulin-like growth factor II. FEBS Lett (1978) 2.56
Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem (1984) 2.55
The avian beta-adrenergic receptor: primary structure and membrane topology. Proc Natl Acad Sci U S A (1986) 2.45
Tumor necrosis factors: gene structure and biological activities. Cold Spring Harb Symp Quant Biol (1986) 2.38
Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med (1984) 2.33
Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A (1991) 2.24
Topology of signal recognition particle receptor in endoplasmic reticulum membrane. Nature (1985) 2.09
Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns. Biochemistry (1988) 2.09
Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol (1986) 2.05
Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol (1993) 1.89
The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol (1990) 1.83
Differential expression of two genes for 1-aminocyclopropane-1-carboxylate synthase in tomato fruits. Proc Natl Acad Sci U S A (1991) 1.83
Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J Exp Med (1988) 1.82
The synergistic anti-proliferative effect of gamma-interferon and human lymphotoxin. J Immunol (1984) 1.81
Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J Leukoc Biol (1987) 1.81
Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res (1988) 1.74
Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol (1989) 1.72
Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem (1985) 1.64
Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II. Proc Natl Acad Sci U S A (1976) 1.58
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol (1991) 1.57
Structure and activity of phosphoglycerate mutase. Philos Trans R Soc Lond B Biol Sci (1981) 1.55
Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation. J Biol Chem (1984) 1.55
Mediation of cardioprotection by transforming growth factor-beta. Science (1990) 1.52
Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol (1987) 1.49
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Functional channel formation associated with cytotoxic T-cell granules. Proc Natl Acad Sci U S A (1986) 1.43
Nonsuppressible insulin-like activity (NSILA) from human serum: recent accomplishments and their physiologic implications. Metabolism (1978) 1.40
Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res (1988) 1.39
Tumor necrosis factor-alpha as a proliferative signal for an IL-2-dependent T cell line: strict species specificity of action. J Immunol (1989) 1.39
Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res (1987) 1.38
Stable isotopes in benthic foraminifera: seasonal variation in large tropical species. Science (1980) 1.35
Purified human interleukin-2 enhances induction of immune interferon. Cell Immunol (1983) 1.33
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33
Purified human growth hormone from E. coli is biologically active. Nature (1981) 1.32
Insulin-like growth factor: a model for tertiary structure accounting for immunoreactivity and receptor binding. Proc Natl Acad Sci U S A (1978) 1.32
Isolation and characterization of an endogenous type C virus of rhesus monkeys. Science (1979) 1.32
Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1. J Exp Med (1990) 1.28
Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor. J Immunol (1993) 1.27
X-ray structure of human relaxin at 1.5 A. Comparison to insulin and implications for receptor binding determinants. J Mol Biol (1991) 1.24
The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction. J Immunol (1988) 1.20
Different forms of Ly-5 within the T-cell lineage. Immunogenetics (1983) 1.20
Antiviral activity of bacteria-derived human alpha interferons against encephalomyocarditis virus infection of mice. Infect Immun (1982) 1.19
Role of oxygen in T cell-mediated cytolysis. J Immunol (1982) 1.18
Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2. J Immunol (1984) 1.17
Design and operation of a completely automated Beckman microsequencer. Anal Biochem (1984) 1.16
Induction of human IgE synthesis by CD4+ T cell clones. Requirement for interleukin 4 and low molecular weight B cell growth factor. J Exp Med (1989) 1.14
Epididymal epithelium: its contribution to the formation of a luminal fluid microenvironment. Microsc Res Tech (1995) 1.13
The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J Biol Chem (1992) 1.11
Interferon-gamma enhances induction of lymphotoxin in recombinant interleukin 2-stimulated peripheral blood mononuclear cells. J Immunol (1985) 1.09
TGF-beta: a possible autocrine immune regulator. Ciba Found Symp (1991) 1.09
Characterization of interleukin 2-dependent cytotoxic T-cell clones: specificity, cell surface phenotype, and susceptibility to blocking by Lyt antisera. Cancer Res (1983) 1.07
The amino acid sequence of yeast phosphoglycerate mutase. Proc R Soc Lond B Biol Sci (1982) 1.06
Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities. Adv Intern Med (1990) 1.06
Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther (2007) 1.05
Amino-terminal sequences of two polypeptides from human serum with nonsuppressible insulin-like and cell-growth-promoting activities: evidence for structural homology with insulin B chain. Proc Natl Acad Sci U S A (1976) 1.05
Bacterial expression of the acquired immunodeficiency syndrome retrovirus p24 gag protein and its use as a diagnostic reagent. Proc Natl Acad Sci U S A (1985) 1.04
Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res (1993) 1.03
In vivo localization of cloned IL-2-dependent T cells. Cell Immunol (1983) 1.02
Mouse Lyt-2 antigen: evidence for two heterodimers with a common subunit. Proc Natl Acad Sci U S A (1982) 1.01
Enantioselective synthesis of the antiinflammatory agent (-)-acanthoic acid. J Org Chem (2001) 1.00
Transforming growth factor-beta and the immune system. Prog Growth Factor Res (1991) 1.00
Comparative large-scale propagation of retroviruses from Old World (Mason-Pfizer monkey virus) and New World (squirrel monkey virus) primates. In Vitro (1978) 1.00
Stereoselective synthesis of (-)-acanthoic acid. Org Lett (2000) 0.99
The antichlamydial, antiviral, and antiproliferative activities of human gamma interferon are dependent on the integrity of the C terminus of the interferon molecule. Infect Immun (1987) 0.98